User profiles for Konstantinos Leventogiannis
 | Konstantinos D. LeventogiannisΑΚΑΔΗΜΑΪΚΟΣ Υπ.- Ε.Κ.Π.Α., ΕΙΔΙΚΟΣ ΠΑΘΟΛΟΓΟΣ Verified email at med.uoa.gr Cited by 523 |
[HTML][HTML] ACTIVATE-2: a double-blind randomized trial of BCG vaccination against COVID-19 in individuals at risk
…, K Dolianitis, A Kotsaki, K Leventogiannis… - Frontiers in …, 2022 - frontiersin.org
In a recent study of our group with the acronym ACTIVATE, Bacillus Calmete-Guérin (BCG)
vaccination reduced the occurrence of new infections compared to placebo vaccination in the …
vaccination reduced the occurrence of new infections compared to placebo vaccination in the …
[HTML][HTML] Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis
Background A subanalysis of a randomized clinical trial indicated sepsis survival benefit
from interleukin (IL)-1 blockade in patients with features of the macrophage activation-like …
from interleukin (IL)-1 blockade in patients with features of the macrophage activation-like …
[PDF][PDF] Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial
K Leventogiannis, E Kyriazopoulou, N Antonakos… - Cell Reports …, 2022 - cell.com
The state of immune activation may guide targeted immunotherapy in sepsis. In a double-blind,
double-dummy randomized clinical study, 240 patients with sepsis due to lung infection, …
double-dummy randomized clinical study, 240 patients with sepsis due to lung infection, …
[HTML][HTML] Effect of a preparation of four probiotics on symptoms of patients with irritable bowel syndrome: association with intestinal bacterial overgrowth
K Leventogiannis, P Gkolfakis, G Spithakis… - Probiotics and …, 2019 - Springer
The effect of probiotics on small intestinal bacterial overgrowth (SIBO) in irritable bowel
syndrome (IBS) has never been studied so far. In this prospective trial, five patients with IBS and …
syndrome (IBS) has never been studied so far. In this prospective trial, five patients with IBS and …
Validation of inflammopathic, adaptive, and coagulopathic sepsis endotypes in coronavirus disease 2019
…, A Kotsaki, A Kanavou, K Leventogiannis… - Critical Care …, 2021 - journals.lww.com
Objectives: Complex critical syndromes like sepsis and coronavirus disease 2019 may be
composed of underling “endotypes,” which may respond differently to treatment. The aim of …
composed of underling “endotypes,” which may respond differently to treatment. The aim of …
[HTML][HTML] Prognostic role of soluble urokinase plasminogen activator receptor at the emergency department: a position paper by the Hellenic sepsis study group
…, P Koutoukas, M Lada, K Leventogiannis… - Infectious diseases and …, 2020 - Springer
In light of the accumulating evidence on the negative predictive value of soluble urokinase
plasminogen activator receptor (suPAR), a group of experts from the fields of intensive care …
plasminogen activator receptor (suPAR), a group of experts from the fields of intensive care …
[HTML][HTML] Presepsin as a diagnostic and prognostic biomarker of severe bacterial infections and COVID-19
E Kyriazopoulou, K Leventogiannis, G Tavoulareas… - Scientific Reports, 2023 - nature.com
We aimed to develop presepsin as a marker of diagnosis of severe infections of either bacterial
and viral origin. The derivation cohort was recruited from 173 hospitalized patients with …
and viral origin. The derivation cohort was recruited from 173 hospitalized patients with …
[HTML][HTML] Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the …
…, A Argyraki, M Negri, K Leventogiannis… - …, 2023 - thelancet.com
Background The SAVE-MORE trial demonstrated that anakinra treatment in COVID-19
pneumonia with plasma soluble urokinase plasminogen activator (suPAR) levels of 6 ng/mL or …
pneumonia with plasma soluble urokinase plasminogen activator (suPAR) levels of 6 ng/mL or …
The association of TSH and thyroid hormones with lymphopenia in bacterial sepsis and COVID-19
…, M Mouktaroudi, K Leventogiannis… - The Journal of …, 2021 - academic.oup.com
Context Lymphopenia is a key feature of immune dysfunction in patients with bacterial sepsis
and coronavirus disease 2019 (COVID-19) and is associated with poor clinical outcomes, …
and coronavirus disease 2019 (COVID-19) and is associated with poor clinical outcomes, …
Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with …
…, M Vlychou, E Petinaki, K Leventogiannis… - European Journal of …, 2021 - Elsevier
Aims Infection by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may lead
to the development of severe respiratory failure. In hospitalized-patients, prompt interruption …
to the development of severe respiratory failure. In hospitalized-patients, prompt interruption …
